151 related articles for article (PubMed ID: 38765008)
1. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.
Holzmayer SJ; Liebel K; Hagelstein I; Salih HR; Märklin M
Front Immunol; 2024; 15():1391954. PubMed ID: 38765008
[TBL] [Abstract][Full Text] [Related]
2. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
[TBL] [Abstract][Full Text] [Related]
3. Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.
Hagelstein I; Lutz MS; Schmidt M; Heitmann JS; Malenke E; Zhou Y; Clar KL; Kopp HG; Jung G; Salih HR; Märklin M; Hinterleitner C
Front Immunol; 2021; 12():653081. PubMed ID: 33936075
[TBL] [Abstract][Full Text] [Related]
4. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
[TBL] [Abstract][Full Text] [Related]
5. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
Zekri L; Lutz M; Prakash N; Manz T; Klimovich B; Mueller S; Hoerner S; Hagelstein I; Engel M; Chashchina A; Pfluegler M; Heitmann JS; Jung G; Salih HR
Mol Ther; 2023 Apr; 31(4):1033-1045. PubMed ID: 36793213
[TBL] [Abstract][Full Text] [Related]
6. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma.
Hagelstein I; Engel M; Hinterleitner C; Manz T; Märklin M; Jung G; Salih HR; Zekri L
Front Immunol; 2022; 13():1002898. PubMed ID: 36275693
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
8. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
[TBL] [Abstract][Full Text] [Related]
9. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
[TBL] [Abstract][Full Text] [Related]
10. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
[TBL] [Abstract][Full Text] [Related]
11. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
12. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
13. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
[TBL] [Abstract][Full Text] [Related]
14. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
15. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
16. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
17. B7-H3 confers resistance to Vγ9Vδ2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis.
Lu H; Ma Y; Wang M; Shen J; Wu H; Li J; Gao N; Gu Y; Zhang X; Zhang G; Shi T; Chen W
Cancer Immunol Immunother; 2021 May; 70(5):1213-1226. PubMed ID: 33119798
[TBL] [Abstract][Full Text] [Related]
18. Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.
Duell J; Lukic DS; Karg M; Reusch U; Koch J; Zhukovsky EA; Rajkovic E; Treder M; Rasche L; Eisele F; Einsele H; Topp MS
J Immunother; 2019 Jun; 42(5):180-188. PubMed ID: 31090657
[TBL] [Abstract][Full Text] [Related]
19. Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
Al-Sukaini A; Hornicek FJ; Peacock ZS; Kaban LB; Ferrone S; Schwab JH
Clin Orthop Relat Res; 2017 Dec; 475(12):3071-3081. PubMed ID: 28725958
[TBL] [Abstract][Full Text] [Related]
20. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.
Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M
Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]